tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2012-2-67-75tumors-117Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSАЛЬТЕРНАТИВНАЯ ЛЕКАРСТВЕННАЯ ТЕРАПИЯ РАКАКорманД. Б.Институт биохимической физики им.Н. М. Эммануэля Российской Академии наук, МоскваRussian Federation201221052015226775Copyright © Корман Д.Б., 20152015Корман Д.Б.Корман Д.Б.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/117

В альтернативной лекарственной терапии рака (АЛТР) можно выделить средства, применяемые для симптоматического лечения больных, и средства, предлагаемые для лекарственного лечения рака. Оставляя в стороне правомочность или неправомочность применения средств АЛТР в этих целях, целесообразно рассмотреть проблему с точки зрения возможности создания на основе средств АЛТР новых противоопухолевых препаратов. Проанализированы данные литературы о результатах изучения противоопухолевых свойств и механизмов действия нескольких наиболее изученных и часто применяемых средств АЛТ(омелы белой, акульего хряща, препарата PC-SPES – комбинации экстрактов 8 лекарственных растений).

Показано, что как эти средства (распространяемые как БАД`ы), так и некоторые из составляющих их индивидуальных химических веществ, способны in vitro подавлять пролиферацию клеток разных опухолей человека, индуцировать в них апоптоз; in vivo ингибировать рост экспериментальных опухолей. Молекулярные механизмы противоопухолевого действия этих веществ опосредованы влиянием на сигнальные пути и ключевые молекулы, регулирующие пролиферацию, гибель (апоптоз), инвазию и миграцию опухолевых клеток, а также блокированием опухолевого неоангиогенеза. Эти данные рассматриваются как доказательства возможности создания на основе средств АЛТР эффективных противоопухолевых препаратов. Однако результаты клинического изучения этих средств и их компонентов весьма противоречивы, большей частью указывают на их неэффективность или низкую эффективность. Рассмотрены возможные причины несоответствия результатов экспериментальных и клинических исследований.

ракальтернативная терапияомела белаяакулий хрящPS-SPESReferencesКорман Д.Б. «Альтернативная терапия рака». Практическая онкология, 2007, №4, 235-244 .Корман Д.Б. «Альтернативная терапия рака». Практическая онкология, 2007, №4, 235-244 .Корман Д.Б. «Зеленый чай – перспективный источник новых противоопухолевых препаратов?» Вопр. онкологии, 2010, №3, 262-271.Корман Д.Б. «Зеленый чай – перспективный источник новых противоопухолевых препаратов?» Вопр. онкологии, 2010, №3, 262-271..Корман Д.Б. «Противоопухолевые свойства лектинов омелы белой». «Вопр.онкологии» , 2011, №6, 689-698 ..Корман Д.Б. «Противоопухолевые свойства лектинов омелы белой». «Вопр.онкологии» , 2011, №6, 689-698 .Корман Д.Б. «Антиангиогенные и противоопухолевые свойства хрящевой ткани». Вопр. онкологии, 2012, №5.Корман Д.Б. «Антиангиогенные и противоопухолевые свойства хрящевой ткани». Вопр. онкологии, 2012, №5.Корман Д.Б. «Средства альтернативной лекарственной терапии рака: Летрил.» Вопр.онкологии 2012, №6.Корман Д.Б. «Средства альтернативной лекарственной терапии рака: Летрил.» Вопр.онкологии 2012, №6.Augustin M., Bock P.R., Hanisch J. et al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate-to high-risk malignant melanoma (UICC/ASCO stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter comparative, epidemiological cohort study in Germany and Switzerland // Arzneimittelforshung. – 2005. – Vol.55. – P.38-49.Augustin M., Bock P.R., Hanisch J. et al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate-to high-risk malignant melanoma (UICC/ASCO stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter comparative, epidemiological cohort study in Germany and Switzerland // Arzneimittelforshung. – 2005. – Vol.55. – P.38-49.Batist G., Patenande F., Champagne P. et al. Neovastat (AE-941) in refractory renal cell carcinoma patients // Ann.oncol. – 2002. – Vo.13. – P.1259-1263.Batist G., Patenande F., Champagne P. et al. Neovastat (AE-941) in refractory renal cell carcinoma patients // Ann.oncol. – 2002. – Vo.13. – P.1259-1263.Bergmann L., Aamdal S., Marreand S. et al. Phase I trial of rviscumin (INN:aviscumine) given subcutaneously in patients with advanced cancer: a study of the European organisation for Research and Treatment of cancer (EORTC protocol number 13001) // Europ.J.Cancer. – 2009. – Vol.44. – P.1657-1662.Bergmann L., Aamdal S., Marreand S. et al. Phase I trial of rviscumin (INN:aviscumine) given subcutaneously in patients with advanced cancer: a study of the European organisation for Research and Treatment of cancer (EORTC protocol number 13001) // Europ.J.Cancer. – 2009. – Vol.44. – P.1657-1662.Bock P.R., Friedel W.E., Hanisch J. et al. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multicenter comparative, epidemiological zerland // Arzneimittelforshung. – 2004. – Vol.54. – P.456-466.Bock P.R., Friedel W.E., Hanisch J. et al. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multicenter comparative, epidemiological zerland // Arzneimittelforshung. – 2004. – Vol.54. – P.456-466.Bonham M., Armed H., Montgomery B., Nelson P.S. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma // Cancer Res. – 2002. – Vol.62. – P.3920-3924.Bonham M., Armed H., Montgomery B., Nelson P.S. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma // Cancer Res. – 2002. – Vol.62. – P.3920-3924.Burger A.M., Mengs U., Schuler J.B., Fiebig H.H. Antiproliferativ action of an aqueous mistletoe extract in human tumor cells lines and xenografts in vitro // Arzneimittelforshung – 2001. – Vol.51. – P.748-757.Burger A.M., Mengs U., Schuler J.B., Fiebig H.H. Antiproliferativ action of an aqueous mistletoe extract in human tumor cells lines and xenografts in vitro // Arzneimittelforshung – 2001. – Vol.51. – P.748-757.Burkhart J., Walche C., Hensser P. et al. In vivo investigation into the potential of mistleroe extract to alleviate adverse effects of cyclophosphamide // Altern.Ther. Heart Med. – 2010. – Vol.16. – P.40-48.Burkhart J., Walche C., Hensser P. et al. In vivo investigation into the potential of mistleroe extract to alleviate adverse effects of cyclophosphamide // Altern.Ther. Heart Med. – 2010. – Vol.16. – P.40-48.Burstein H.J. Discussing complementary therapies with cancer patients: what should we talking about?// J.Clin.Oncol.-2000-Vol.18.-P.2501-2504Burstein H.J. Discussing complementary therapies with cancer patients: what should we talking about?// J.Clin.Oncol.-2000-Vol.18.-P.2501-2504Cassileth B.R., Vickers A.J. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care// J.Clin.Oncol. -2005. – Vol.23. – P.2590-2592Cassileth B.R., Vickers A.J. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care// J.Clin.Oncol. -2005. – Vol.23. – P.2590-2592de Lemos M.L. Herbal supplement PC-SPES for prostatic cancer // Ann.Pharmacother. – 2002. – Vol.36. – P.921-926/de Lemos M.L. Herbal supplement PC-SPES for prostatic cancer // Ann.Pharmacother. – 2002. – Vol.36. – P.921-926/Dupont E., Folardeau P., Mousa S.A. et al. Antiangiogenic and antimetastic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue // Clin.Exp. Metastasis. – 2002. – Vol.19. – P.145-153.Dupont E., Folardeau P., Mousa S.A. et al. Antiangiogenic and antimetastic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue // Clin.Exp. Metastasis. – 2002. – Vol.19. – P.145-153.Falardeau P., Champaguel P., Poyet P. et al. Neovastat, a naturally occuring multifunctional antiangiogenic drug, in phase III clinical trials // Semin.Oncol. – 2001. – Vol.28. – P.620-625.Falardeau P., Champaguel P., Poyet P. et al. Neovastat, a naturally occuring multifunctional antiangiogenic drug, in phase III clinical trials // Semin.Oncol. – 2001. – Vol.28. – P.620-625.Fitzgerald F.T. Choices in healing: integrating the best of conventional and complementary approaches to cancer//New Engl.J.Med. – 1994. – Vol.331. – P.1244-1248.Fitzgerald F.T. Choices in healing: integrating the best of conventional and complementary approaches to cancer//New Engl.J.Med. – 1994. – Vol.331. – P.1244-1248.Friendel W.E., Matthes H., Bock P.R., Zanker K.S. Systematic evaluation of the clinical effects of supportive mistletoe treatment with chemo-and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: controlled, observational cohort study // J.Soc.Integr.Oncol. – 2009. – Vol.7. – P.137-145.Friendel W.E., Matthes H., Bock P.R., Zanker K.S. Systematic evaluation of the clinical effects of supportive mistletoe treatment with chemo-and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: controlled, observational cohort study // J.Soc.Integr.Oncol. – 2009. – Vol.7. – P.137-145.Gingras D., Boivin D., Deckers C. et al. Neovastat – a novel antiangiogenic drug for cancer therapy // Anticancer Res. 2003. – Vol.14. – P.91-96Gingras D., Boivin D., Deckers C. et al. Neovastat – a novel antiangiogenic drug for cancer therapy // Anticancer Res. 2003. – Vol.14. – P.91-96Growing interest in complementary and alternative cancer therapies//Ca:CancerJ.Clin. – 2004. – Vol.54. – P.286-288.Growing interest in complementary and alternative cancer therapies//Ca:CancerJ.Clin. – 2004. – Vol.54. – P.286-288.Horneberr M.A., Bueschel G., Huber R. et al. Mistletoe therapy in oncology // Cochrane Database Syst. Rev. – 2008. – apr.16 (2) : CD 003297.Horneberr M.A., Bueschel G., Huber R. et al. Mistletoe therapy in oncology // Cochrane Database Syst. Rev. – 2008. – apr.16 (2) : CD 003297.Hyodo I.,Amano N., Eguchi K. et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan//J.Clin.Oncol. – 2005.- Vol.23. – P.2645-2654.Hyodo I.,Amano N., Eguchi K. et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan//J.Clin.Oncol. – 2005.- Vol.23. – P.2645-2654.Ikezoe T., Chen S.S., Yang Y.et al. PS-SPES: molecular mechanisms to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells // Int.J.Oncol. – 2003. – Vol.23. – P.1461-1470.Ikezoe T., Chen S.S., Yang Y.et al. PS-SPES: molecular mechanisms to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells // Int.J.Oncol. – 2003. – Vol.23. – P.1461-1470.Kosty M.P. PC-SPES: Hope or hype // J.Clin.Oncol. – 2004. – Vol.22. – P.3667-3669.Kosty M.P. PC-SPES: Hope or hype // J.Clin.Oncol. – 2004. – Vol.22. – P.3667-3669.Kubota T., Hisatake J., Hisatake Y. et al. PC-SPES: an unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo // Prostate. – 2000. – Vol.42. – P.163-171.Kubota T., Hisatake J., Hisatake Y. et al. PC-SPES: an unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo // Prostate. – 2000. – Vol.42. – P.163-171.LatrelleJ., Batist G., Laberge F. et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small- cell lung cancer // Clin.Lung Cancer - -2003. – Vol.4. – P.231-236.LatrelleJ., Batist G., Laberge F. et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small- cell lung cancer // Clin.Lung Cancer - -2003. – Vol.4. – P.231-236.Loprinzi O.L.,Levitt R., Barton D.L. et al. Evaluation of shark cartilage in patients with advanced cancer // Cancer – 2005. – Vol.104. – P.176-182Loprinzi O.L.,Levitt R., Barton D.L. et al. Evaluation of shark cartilage in patients with advanced cancer // Cancer – 2005. – Vol.104. – P.176-182Lu X., Guo J., Hsieh T.C. PC-SPES inhibits cell proliferation by modulating p21m cyclin D,E and B and multiple cell cycle-related genes in prostate cancer cells // Cell cycle. – 2003. – Vol.2. - P.59-63.Lu X., Guo J., Hsieh T.C. PC-SPES inhibits cell proliferation by modulating p21m cyclin D,E and B and multiple cell cycle-related genes in prostate cancer cells // Cell cycle. – 2003. – Vol.2. - P.59-63.Lu C., Lee J., Komaki R. et al. Chemoradiotherapy with and without AE-941 in stage III non-small cell lung cancer: randomized phase III trial // J.Natl.Cancer Inst. - 2010. – Vol.102. – P.859-865.Lu C., Lee J., Komaki R. et al. Chemoradiotherapy with and without AE-941 in stage III non-small cell lung cancer: randomized phase III trial // J.Natl.Cancer Inst. - 2010. – Vol.102. – P.859-865.Melzer J., Iten F., Hostanski K., Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review // Forch. Komplement.Med. – 2009. – Vol 16. - P.217-226.Melzer J., Iten F., Hostanski K., Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review // Forch. Komplement.Med. – 2009. – Vol 16. - P.217-226.Meyer J.P., Gillatt D.A. PS-SPES: a herbal therapy for the treatment of hormone refractory prostate cance // Prostatic Dis. – 2002. – Vol.5. – P.13-15.Meyer J.P., Gillatt D.A. PS-SPES: a herbal therapy for the treatment of hormone refractory prostate cance // Prostatic Dis. – 2002. – Vol.5. – P.13-15.Oh W.K., Kantoff P.W., Weinberg V. et.al. Prospec tive, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer // J.Clin.Oncol. – 2004/ - Vol.22. – P.3705-3712.Oh W.K., Kantoff P.W., Weinberg V. et.al. Prospec tive, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer // J.Clin.Oncol. – 2004/ - Vol.22. – P.3705-3712.Penson R.T., CastroC.M., Seiden M.V. et al. Complementary, alternative integrative or unconventional medicine ?// The Oncologist. -2001.- Vol.6. -P. 63-473Penson R.T., CastroC.M., Seiden M.V. et al. Complementary, alternative integrative or unconventional medicine ?// The Oncologist. -2001.- Vol.6. -P. 63-473Richardson M.A., Sandlers T., Palmer J.L. Complementary/ alternative medicine use in a comprehensive cancer center and the implications for oncology/ / J.Clin. Oncol. – 2000. – Vol.18. – P.2505-2514.Richardson M.A., Sandlers T., Palmer J.L. Complementary/ alternative medicine use in a comprehensive cancer center and the implications for oncology/ / J.Clin. Oncol. – 2000. – Vol.18. – P.2505-2514.Small E.J., Frohlich M.W., Bon R. et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer // J.Clin.Oncol. – 2000. – Vol.18. – P.3595-3603.Small E.J., Frohlich M.W., Bon R. et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer // J.Clin.Oncol. – 2000. – Vol.18. – P.3595-3603.Tascilar M., de Jong F.A., Verweij J. et al.Complementary and alternative medicine during cancer treatment: beyond innocence//The Oncologist. – 2006. –Vol.11. – P.732-741.Tascilar M., de Jong F.A., Verweij J. et al.Complementary and alternative medicine during cancer treatment: beyond innocence//The Oncologist. – 2006. –Vol.11. – P.732-741.Vickers A. Alternative cancer cures: “unproven” or “disproven”// Ca:Cancer J.Clin. -2004. – Vol.54. – P.110-118.Vickers A. Alternative cancer cures: “unproven” or “disproven”// Ca:Cancer J.Clin. -2004. – Vol.54. – P.110-118.Vickers A.J., Kuo J., Cassieth B.R. Unconventional anticancer agents: a systematic review of clinical trials//J. Clin.Oncol. – 2006. –Vol.24. – P.136-140.Vickers A.J., Kuo J., Cassieth B.R. Unconventional anticancer agents: a systematic review of clinical trials//J. Clin.Oncol. – 2006. –Vol.24. – P.136-140.Vickers A.J. Which botanicals or other unconventional anticancer agents should be take to clinical trial?//J.Soc.Integr.Oncol. – 2007. – Vol.5. – P.125-129.Vickers A.J. Which botanicals or other unconventional anticancer agents should be take to clinical trial?//J.Soc.Integr.Oncol. – 2007. – Vol.5. – P.125-129.Weiger W.A., Smith M., Boon H. et al. Advising patients who seek complementary and alternative medical therapies for cancer// Ann.Inter.Med. -2002. – Vol.137. – P.889-903.Weiger W.A., Smith M., Boon H. et al. Advising patients who seek complementary and alternative medical therapies for cancer// Ann.Inter.Med. -2002. – Vol.137. – P.889-903.White J. PC-SPES – a lesson for future dactary supplement research // J.Nat./Cancer Inst. – 2002. – Vol.94. – 1261-1263.White J. PC-SPES – a lesson for future dactary supplement research // J.Nat./Cancer Inst. – 2002. – Vol.94. – 1261-1263.Ziegler R. Mistletoe preparation Iscador: are there methodological concerns with respect to controlled clinical trials // eCAM – 2009. – Vol.6.- P.19-30.Ziegler R. Mistletoe preparation Iscador: are there methodological concerns with respect to controlled clinical trials // eCAM – 2009. – Vol.6.- P.19-30.

The authors declare that there are no conflicts of interest present.